Shares of Allergan plc Ordinary Shares (NYSE:AGN) ended Wednesday session in red amid volatile trading. The shares closed down -0.70 points or -0.29% at $238.42 with 2.32 million shares getting traded. Post opening the session at $239.12, the shares hit an intraday low of $236.04 and an intraday high of $241.49 and the price vacillated in this range throughout the day. The company has a market cap of $94.68 billion and the numbers of outstanding shares have been calculated to be 395.95 million shares.
On Sept. 7, 2016 Medicines360, a nonprofit global women’s health pharmaceutical company, and Allergan, plc (AGN), a leading global pharmaceutical company, announced the publication of five-year levonorgestrel release rates for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg in the September 2016 issue of the medical journal Contraception.
“This study was conducted to understand the duration of action for LILETTA,” said lead author Mitchell Creinin, MD, Professor and Director of Family Planning in the Department of Obstetrics and Gynecology at the University of California, Davis.
The study evaluated the remaining hormone content in LILETTA systems that had been removed from women at various time points during the first five years of the ongoing seven-year ACCESS IUS (A Comprehensive Contraceptive Efficacy and Safety Study of an IUS) clinical trial, the largest ever IUS clinical trial conducted in the US. The remaining amount of levonorgestrel, the active hormone in LILETTA, was used to calculate the hormone release rate over five years.
“The study’s findings,” according to Dr. Creinin, “show that the amount of levonorgestrel remaining in the system and the amount still being released each year support the continued evaluation of LILETTA as a contraceptive for up to five years.”
Shares of Celgene Corporation (NASDAQ:CELG) ended Wednesday session in green amid volatile trading. The shares closed up +0.25 points or 0.23% at $106.96 with 3.10 million shares getting traded. Post opening the session at $106.73, the shares hit an intraday low of $106.30 and an intraday high of $107.91 and the price vacillated in this range throughout the day. The company has a market cap of $83.87 billion and the numbers of outstanding shares have been calculated to be 775.11 million shares.
Celgene Corporation (CELG) plans to present upcoming investor conferences and at an R&D deep dive in September where Celgene management will provide an overview of the Company. The conferences and R&D deep dive will be webcast live and the webcasts will be available in the Investor Relations section of the Company’s website at www.celgene.com.
Monday, September 12, 2016, Celgene will present at the Morgan Stanley Global Healthcare Unplugged Conference in New York City at 2:50 pm ET
Thursday, September 29, 2016, Celgene will webcast an R&D Deep Dive on Protein Homeostasis beginning at 1:30pm ET. The webcast is expected to conclude at 5pm ET.